Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 1Solid Tumor, Adult 1Salivary Gland Neoplasms 1Neoplasm Metastasis 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Cisplatin 4Carboplatin 4Biopsy 4trastuzumab deruxtecan 3Trastuzumab 3Platinum 3Goserelin 3Docetaxel 3sacituzumab govitecan 2pertuzumab 2entrectinib 2darolutamide 2Radiotherapy, Intensity-Modulated 2Leuprolide 2Ado-Trastuzumab Emtansine 21,2-diaminocyclohexaneplatinum II citrate 2zanidatamab 1trastuzumab biosimilar HLX02 1spartalizumab 1selinexor 1pyrotinib 1luprolide acetate gel depot 1lenvatinib 1larotrectinib 1enfortumab vedotin 1dehydroftorafur 1ceralasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × amivantamab × 1 year × Clear all
NCT05074940 2026-05-08

Amivantamab in Adenoid Cystic Carcinoma

University of Cincinnati

Phase 2 Active not recruiting
21 enrolled 13 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡